Evidence map›Paper›PMID 32533449›Full record

ArticleEJNMMI research2020

Human biodistribution and internal dosimetry of 4-[

Cameron D Pain, Graeme J O'Keefe, Uwe Ackermann, Vincent Dore, Victor L Villemagne, Christopher C Rowe

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Cameron D PainDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia. cameron.pain@austin.org.au.ORCID http://orcid.org/0000-0002-6294-036X
Graeme J O'KeefeDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia.
Uwe AckermannDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia.
Vincent DoreDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia.
Victor L VillemagneDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia.
Christopher C RoweDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia.
Austin Health · AUThe University of Melbourne · AUCommonwealth Scientific and Industrial Research Organisation · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background4-[

methodDose calculations were based on activity uptake derived from multiple time point whole body PET CT imaging and the organ-specific dosimetric S-factors derived from the ICRP 133 standard man and woman mathematical phantoms. Effective doses were calculated using the latest ICRP tissue weighting factors.

resultsSerial images and time activity curves demonstrate high brain and left ventricular myocardial uptake (5% and 0.65% of injected activity, respectively) with greater retention in brain than myocardium. The mean effective dose was in concordance with other

conclusionsThe radiation dose associated with an administration of F-DEX is comparable to that of other

Indexed as

4-[ 18F]fluorobenzyl dexetimideMuscarinic cholinergic neuroreceptorsPositron emission tomographyRadiation dosimetry

Identifiers

PMID32533449
PMCPMC7292855
OpenAlexW3034281246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.